bioRxiv Science⌕ Search

Biology subjects

Aleshin, V. A.

Publications and source records attributed to Aleshin, V. A..

2 recordsLinked to original sources

Protein-protein interfaces as druggable targets: A common motif of the pyridoxal-5'-phosphate-dependent enzymes to receive the coenzyme from its producers

Pyridoxal-5-phosphate (PLP), a phosphorylated form of vitamin B6, acts as a coenzyme for numerous reactions, including those changed in cancer and/or associated with the disease prognosis. Since highly reactive PLP may modify cellular proteins, it is hypothesized to be directly transferred from its donors to acceptors. Our goal is to validate the hypothesis by finding common motif(s) in a multitude of the PLP-dependent enzymes for binding the limited number of the PLP donors, namely pyridoxal kinase (PdxK), pyridox(am)in-5-phosphate oxidase (PNPO) and the PLP-binding protein (PLPBP). Experimentally confirmed interactions between the PLP donors and acceptors reveal that PdxK and PNPO interact with the PLP acceptors of folds I and II, while PLPBP - with those of folds III and V. Aligning the sequences and 3D structures of the identified interactors of PdxK and PNPO, we have found a common motif in the PLP-dependent enzymes of folds I and II. The motif extends from the enzyme surface to the neighborhood of the PLP binding site, represented by an exposed alfa-helix, a partially buried beta-strand and residual loops. Pathogenicity of mutations in human PLP-dependent enzymes within or in the vicinity of the motif, but outside of the active sites, supports functional significance of the motif that may provide an interface for the direct transfer of PLP from the sites of its synthesis to those of the coenzyme binding. The enzyme-specific amino acid residues of the common motif may be useful to develop selective inhibitors blocking PLP delivery to the PLP-dependent enzymes critical for proliferation of malignant cells.

biochemistry↗

Inhibition of pyruvate dehydrogenase affects the brain protein acylation stronger than PDHA phosphorylation at Ser293

Adaptation of an organism to metabolic challenges requires mechanisms coupling metabolism to gene expression. Acylations of metabolic and histone proteins acquire significant attention in this regard. We hypothesize that adaptive response to inhibition of a key metabolic process, catalyzed by the acetyl-CoA-generating pyruvate dehydrogenase (PDH) complex, may be mediated by changed protein acylations. The hypothesis is tested by intranasal administration to animals of PDH-specific inhibitors acetylmethylphosphinate (AcMeP) or methyl ester of acetylphosphonate (AcPMe), followed by assessment of physiological parameters, brain protein acylation system and expression/phosphorylation of PDHA subunit. At a fixed dose, AcMeP, but not AcPMe, decreases acetylation and increases succinylation of the brain proteins of apparent molecular mass of 15-20 kDa. Regarding the 30-50 kDa proteins, a strong inhibitor AcMeP affects acetylation only, while a less efficient AcPMe mostly increases succinylation. No increase in the succinylation of the 30-50 kDa proteins by AcMeP coincides with its induction of desuccinylase SIRT5, not observed in the AcPMe-treated animals. The brain PDHA expression or phosphorylation, the animal behavior or ECG do not significantly differ between the studied animal groups. The data indicate that a short-term inhibition of the brain PDH affects acetylation and/or succinylation of the brain proteins, dependent on the inhibitor potency, protein molecular mass and acylation type. Homeostatic nature of these changes is implied by stability of physiological parameters after the PDH inhibition.

biochemistry↗